Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN-1012
- Development stage
- Unknown
- Lead developer
- Naeja
- Modality
- Small Molecules
01
Overview
SYN-1012 is an experimental small molecule beta-lactamase inhibitor developed by Naeja Pharmaceutical (formerly SynPhar Laboratories). It was designed to address antibiotic resistance by inhibiting the beta-lactamase enzymes produced by bacteria, which otherwise degrade beta-lactam antibiotics such as penicillins and cephalosporins. As part of Naeja's "SYN" series of infectious disease candidates, SYN-1012 was intended to be used in combination with existing antibiotics to restore their efficacy against resistant strains. The compound was primarily researched in the preclinical stage, and development has since been discontinued following the cessation of Naeja's active internal pipeline programs.
02
Targets
Neuraminidase
Beyond the preview
Go deeper on SYN-1012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN-1012.